Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Mathieu Métifiot"'
Autor:
Chloé Torres, Asja Garling, Saïd Taouji, Christina Calmels, Marie-Line Andreola, Mathieu Métifiot
Publikováno v:
Molecules, Vol 26, Iss 17, p 5423 (2021)
Multiple viral targets are now available in the clinic to fight HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in patients due to resistance, with
Externí odkaz:
https://doaj.org/article/ee205c82514f4ab9869b13e2b16737d7
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Mosquito- and tick-borne pathogens including Chikungunya, Dengue, Japanese encephalitis, West Nile, Yellow fever and Zika virus, represent a new economic and public health challenge. In the absence of effective vaccines and specific therapie
Externí odkaz:
https://doaj.org/article/5d7e140debe44068a932d7d7642b5a5f
Publikováno v:
Biochimie
Biochimie, 2021, ⟨10.1016/j.biochi.2021.11.003⟩
Biochimie, 2021, ⟨10.1016/j.biochi.2021.11.003⟩
As ZIKV continues to spread, many “unknowns” remain and research is needed to advance the understanding of this important pathogen. Viral RNA dependent-RNA polymerases (RdRp) are validated targets for inhibitors of the replication of several viru
Autor:
Nicole Grandi, Enzo Tramontano, Francesca Esposito, Davide Ialongo, Alessandro De Leo, Giorgio Amendola, Daniela De Vita, Antonella Messore, Valentina Noemi Madia, Marie-Line Andreola, Ettore Novellino, Mathieu Métifiot, Sandro Cosconati, Roberta Costi, Angela Corona, Roberto Di Santo, Valeria Tudino, Francesco Saccoliti, Luigi Scipione
Publikováno v:
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, American Chemical Society, 2021, 64 (12), pp.8579-8598. ⟨10.1021/acs.jmedchem.1c00535⟩
Journal of Medicinal Chemistry, American Chemical Society, 2021, 64 (12), pp.8579-8598. ⟨10.1021/acs.jmedchem.1c00535⟩
Novel anti-HIV agents are still needed to overcome resistance issues, in particular inhibitors acting against novel viral targets. The ribonuclease H (RNase H) function of the reverse transcriptase (RT) represents a validated and promising target, an
Autor:
Guillaume Beucher, Marie-Lise Blondot, Alexis Celle, Noémie Pied, Patricia Recordon-Pinson, Pauline Esteves, Muriel Faure, Mathieu Métifiot, Sabrina Lacomme, Denis Dacheux, Derrick R. Robinson, Gernot Längst, Fabien Beaufils, Marie-Edith Lafon, Patrick Berger, Marc Landry, Denis Malvy, Thomas Trian, Marie-Line Andreola, Harald Wodrich
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 (28), ⟨10.1073/pnas.2202370119⟩
Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 (28), ⟨10.1073/pnas.2202370119⟩
International audience; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections initiate in the bronchi of the upper respiratory tract and are able to disseminate to the lower respiratory tract, where infections can cause an acute res
Autor:
Xue Zhi Zhao, Mathieu Métifiot, Evgeny Kiselev, Jacques J. Kessl, Kasthuraiah Maddali, Christophe Marchand, Mamuka Kvaratskhelia, Yves Pommier, Terrence R. Burke
Publikováno v:
Molecules, Vol 23, Iss 8, p 1858 (2018)
HIV-1 integrase (IN) inhibitors represent a new class of highly effective anti-AIDS therapeutics. Current FDA-approved IN strand transfer inhibitors (INSTIs) share a common mechanism of action that involves chelation of catalytic divalent metal ions.
Externí odkaz:
https://doaj.org/article/4c907d36f6b14c509e53863d153aad7a
Publikováno v:
Viruses, Vol 2, Iss 7, Pp 1347-1366 (2010)
Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to t
Externí odkaz:
https://doaj.org/article/47083e6679e744a6809e556ddb5f9937
Autor:
Gontran Ondzotto, Patricia Recordon-Pinson, Marie-Lise Blondot, Ferdinand Emaniel Brel Got, Ghislain Loubano-Voumbi, Dagene Ebourombi, Mathieu Métifiot, Marie-Line Andreola
Publikováno v:
Microorganisms; Volume 9; Issue 11; Pages: 2355
Microorganisms
Microorganisms, MDPI, 2021, 9 (11), pp.2355. ⟨10.3390/microorganisms9112355⟩
Microorganisms, Vol 9, Iss 2355, p 2355 (2021)
Microorganisms
Microorganisms, MDPI, 2021, 9 (11), pp.2355. ⟨10.3390/microorganisms9112355⟩
Microorganisms, Vol 9, Iss 2355, p 2355 (2021)
International audience; Background: HIV infects around one hundred thousand patients in the Republic of the Congo. Approximately 25% of them receive an antiretroviral treatment; current first-line regimens include two NRTIs and one NNRTI, reverse tra
Autor:
Marie-Lise Blondot, Marc Landry, A. Celle, Pauline Esteves, Patrick Berger, Harald Wodrich, Patricia Recordon-Pinson, Marie-Edith Lafon, Marie-Line Andreola, Derrick R. Robinson, Fabien Beaufils, Thomas Trian, Denis Malvy, Mathieu Métifiot, Noémie Pied, Denis Dacheaux, Muriel Faure, Guillaume Beucher, Gernot Längst, Sabrina Lacomme
The beta-coronavirus SARS-CoV-2 is at the origin of a persistent worldwide pandemic. SARS-CoV-2 infections initiate in the bronchi of the upper respiratory tract and are able to disseminate to the lower respiratory tract eventually causing acute seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8468acc9bb2828a5494a8793d8637ea
https://hal.archives-ouvertes.fr/hal-03375199/file/2021.05.28.446159v1.full.pdf
https://hal.archives-ouvertes.fr/hal-03375199/file/2021.05.28.446159v1.full.pdf
Autor:
Mathieu Métifiot, Patricia Recordon-Pinson, Marie-Edith Lafon, Marie-Lise Blondot, Pantxika Bellecave, Camille Tumiotto, Marie-Line Andreola
Publikováno v:
COVID
COVID, MDPI, 2021, 1 (1), pp.337-344. ⟨10.3390/covid1010028⟩
COVID, MDPI, 2021, 1 (1), pp.337-344. ⟨10.3390/covid1010028⟩
International audience; Since the beginning of the pandemic, a race has been underway to detect SARS-CoV-2 virus infection (PCR screening, serological diagnostic kits), treat patients (drug repurposing, standard care) and develop a vaccine. After alm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07c70ea6769e99c8de8019be552fbc9
https://hal.archives-ouvertes.fr/hal-03364618/document
https://hal.archives-ouvertes.fr/hal-03364618/document